What's new with insulin? Jeppe Sturis and his team at Novo Nordisk have a new hypothesis. They challenge the long-held belief that insulin resistance comes from faulty tissues, suggesting instead that the real culprit is insulin breaking down before it even reaches its target. This fresh perspective could reshape how we fight diabetes.We will also hear from Diamyd Medical’s advancing research on antigen-specific immunotherapy which could change the game by protecting insulin-producing cells and slowing the progression of Type 1 diabetes.